Novo’s broad Flagship partnership starts with obesity at Omega and MASH at Cellarity
Novo Nordisk and Flagship Pioneering unveiled the first two research tie-ups involved in their sprawling cardiometabolic partnership on Thursday morning.
The pair is employing Omega Therapeutics to work on an mRNA therapeutic for obesity and Cellarity to work on a small molecule for metabolic dysfunction-associated steatohepatitis. Both companies were founded by the life sciences incubator.
Novo will pay Omega and Flagship’s Pioneering Medicines up to $532 million across upfront payments and biobucks, plus tiered royalties. The same structure applies to Cellarity and Pioneering Medicines, the companies said. Novo will also reimburse R&D costs as the partners work together on preclinical development. The drug giant, flush with cash from its semaglutide franchise, can then choose to handle clinical studies, which are years away, and further development.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.